Should You Buy Goldman Sachs Stock After Its Investment Banking Fees Surged in Q1?

Goldman Sachs posted a blowout Q1, with revenue up 14% year over year to $17.2 billion and net income rising to $5.6 billion, or $17.55 per share. Investment banking revenue surged 48% to $2.84 billion, helped by a record-high four-year backlog of M&A deals and a 50% jump in global deal value. The stock has risen about 7% in the past month and roughly 9% year to date as investors price in sustained M&A strength.

Analysis

The important read-through is not just that GS is levered to M&A, but that advisory is becoming the marginal driver of operating leverage at a point in the cycle when the market is still discounting “normalized” investment banking. If the backlog is indeed at a multi-year high, the next 2-3 quarters should show unusually sticky fee conversion, because announced deals tend to monetize with a lag and the current pipeline appears to be skewed toward larger, higher-fee transactions. That makes GS the cleanest expression of a deal-cycle upswing versus JPM and MS, which have more diversified earnings buffers and therefore less convex upside to a rebound in advisory.

The second-order effect is that a sustained M&A wave usually signals rising confidence in balance-sheet deployment across sectors, which can spill into lower-quality credit and sponsor activity before it shows up in headline equity volumes. That matters for the private credit ecosystem: if funding spreads stay orderly, the credit providers win via origination and refinancing fees; if they gap wider, GS’s institutional funding mix gives it relative insulation, but the broader deal machine slows only after a multi-month pause, not immediately. In other words, the near-term risk is not volume collapse but deal delay, which would hit the stock only after expectations get stretched.

The contrarian issue is valuation duration, not absolute valuation. A 15x forward multiple looks cheap versus the quality of the franchise, but the market may already be underwriting a decent part of the cycle extension; if rates fail to fall in 2026 or geopolitical shocks freeze boardroom activity, the backlog becomes a timing issue rather than a value creation engine. The upside case is still attractive because the earnings revision cycle should outrun multiple compression as long as advisory conversion stays strong into the next two quarters.

Key Decisions for Investors

• Long GS versus JPM or MS for the next 1-2 quarters; GS should have the highest earnings convexity if M&A backlog converts, while the peers’ more diversified mixes cap upside. Target: relative outperformance of 5-8% if deal activity holds.
• Buy GS on any 3-5% pullback rather than chasing strength; the risk/reward improves if the market sells the stock on macro headlines while the backlog stays intact. Stop if advisory commentary weakens or announced deal counts roll over for two consecutive months.
• Use a call spread on GS (3-6 month tenor) to express continued M&A strength with defined downside; best setup if implied vol remains below recent event-driven peaks. Favor strikes around 5-10% above spot to monetize earnings revision momentum.
• Pair long GS / short a rate-sensitive regional bank basket if you want to isolate capital-markets upside from broader banking credit risk. The trade benefits if underwriting optimism improves without a corresponding rise in loan-loss anxiety.
• If you want a contrarian hedge, short-dated downside puts on GS only make sense if deal-announcement momentum stalls; otherwise the path of least resistance is higher over the next 1-2 quarters. Reassess after the next earnings call and monthly M&A data prints.